^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MT-3724

    i
    Associations
    News

    Trials

    Company:
    Molecular Templates
    Drug class:
    CD20 inhibitor, Apoptosis stimulant, Protein synthesis inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT02556346)
    Phase 1
    Molecular Templates, Inc.
    Withdrawn
    Last update posted :
    03/02/2016
    Initiation :
    11/01/2015
    Primary completion :
    08/01/2016
    Completion :
    12/01/2016
    CD5
    |
    MT-3724